LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cel ...

Vertex Pharmaceuticals (VRTX -0.04%) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been expanding into other areas as well. Last year, Vertex's shares rose by just under 41%, easily outperforming the S&P 500, which increased by a still-respectable 24%.Can this biotech continue rallying after posting its latest earnings numbers, or has it become too expensive?Vertex's growth rate is slowing downOn Feb. 5, ...

Vertex Pharmaceuticals Incorporated (VRTX) reported fourth-quarter 2023 adjusted earnings per share of $4.20, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 12% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings in the reported quarter.Revenues of $2.52 billion surpassed the Zacks Consensus Estimate of $2.49 billion. Revenues solely comprised CF product revenues. Total product revenues rose 9.3% year over year, primarily driven by higher sales of Trik ...

Biotech giant Vertex Pharmaceuticals (VRTX 0.99%) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod in several countries. This development capped off another excellent year for the drugmaker, one during which -- as usual -- it crushed the market.However, at least on the clinical front, Vertex isn't exactly starting 2024 with a bang. The company recently released positive but somewhat disappointing data from a ph ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2023 Earnings Conference Call February 5, 2024 5:00 PM ET Company Participants Susie Lisa - CFA, Senior Vice President of Investor Relations Reshma Kewalramani - President & Chief Executive Officer Stuart Arbuckle - Executive Vice President & Chief Operating Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Mohit Bansal - Wells Fargo Phil ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.20 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.44%. A quarter ago, it was expected that this drugmaker would post earnings of $3.92 per share when it actually produced earnings of $4.08, delivering a surprise of 4.08%.Over the last four quarters, the c ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program, the most comprehensive Phase 3 pivotal program ever conducted by Vertex for the treatment of cystic fibrosis (CF), a progressive, multi-organ disease caused by dysfunction of the CFTR protein. The Phase 3 program included two randomized, double-blind, active-controlled, 52-week trials, SKYLINE 102 and SKYLINE 103, ...

Vertex Pharmaceuticals (VRTX -2.12%) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area when it won approval with partner CRISPR Therapeutics for a gene editing therapy for blood disorders.Next, Vertex is about to show that it can conquer one of the world's most common health problems: pain. The company recently reported positive phase 3 data for VX-548, its treatment candidate for moderate-to-severe ...

Vertex Pharmaceuticals (VRTX) announced positive results from three late-stage studies on its investigational orally-administered non-opioid pain medicine, VX-548, to treat moderate-to-severe acute pain.The company evaluated VX-548, a novel first-in-class NaV1.8 inhibitor, in two pivotal phase III acute pain studies — one following bunionectomy surgery and the other following abdominoplasty surgery. The studies achieved their primary endpoint — treatment with VX-548 showed a significant reduction in pain in ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $4.08 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $2.5 billion, representing an increase of 8.5% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during ...